Are new migraine drugs causing a headache to investors?

Meg Tirrell reports on a group of migraine drug manufacturers that missed expectations on earnings and is causing investors to worry.

This entry was posted in Health Care, NBR Show Clips. Bookmark the permalink.

Leave a Reply